文献速递慢阻肺呼吸道感染

阿奇霉素暴露与支气管扩张及慢阻肺中非结核分枝杆菌分离:全国性巢式病例对照研究

Azithromycin Exposure and Incident Nontuberculous Mycobacterial Isolation in Bronchiectasis and COPD: A Nationwide Nested Case-Control Study.
PubMed 文献 · Chest · 2026-10-28

丹麦全国性巢式病例对照研究探讨既往一年阿奇霉素暴露与non-CF支气管扩张和慢阻肺患者新发呼吸道NTM分离的关联。预设暴露定义(≥3000mg且≥2次配药)下,阿奇霉素与NTM分离无显著关联(支气管扩张OR 1.31,95%CI 0.79-2.18;慢阻肺OR 1.29,95%CI 0.78-2.13)。慢阻肺中较宽定义关联集中于近90天且随微生物学严格性减弱,提示适应证驱动检测而非药物效应。

要点

  • 预设高剂量阿奇霉素暴露未增加支气管扩张或慢阻肺患者NTM分离风险。
  • 慢阻肺中任何处方暴露与NTM分离的关联集中于近90天,非剂量依赖。
  • 非大环内酯类抗菌药在多个阈值下与NTM分离的关联强于阿奇霉素。

核心结论

  • 预设定义下阿奇霉素与NTM分离无显著关联,宽泛定义下的关联更可能反映适应证驱动的检测而非药物效应。

研究设计与样本

  • 丹麦全国性登记巢式病例对照研究,支气管扩张组173例病例和3409例对照,慢阻肺组365例病例和7300例对照,按年龄、性别和合并症指数1:20匹配。

主要发现

  • 预设定义下支气管扩张OR 1.31(95%CI 0.79-2.18),慢阻肺OR 1.29(95%CI 0.78-2.13)。
  • 慢阻肺中≥1次处方OR 1.61(95%CI 1.14-2.28),≥2次处方OR 1.29(95%CI 0.78-2.13)。
  • 慢阻肺中关联集中于索引日期90天内(OR 2.55,95%CI 1.73-3.76),严格微生物学定义下减弱(明确分离株OR 0.77,95%CI 0.27-2.20)。
  • 支气管扩张中非大环内酯类抗菌药在≥1次处方阈值关联强于阿奇霉素(1.90 [1.36-2.65] vs 1.15 [0.75-1.75])。
  • 慢阻肺中非大环内酯类抗菌药在≥2次处方阈值关联强于阿奇霉素(1.48 [1.17-1.86] vs 1.24 [0.75-2.05])。

临床怎么用

  • 临床对接受阿奇霉素的支气管扩张或慢阻肺患者出现NTM分离时,应结合暴露时间及检测指征综合判断,避免简单归因于药物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Azithromycin reduces exacerbations in chronic airway disease, but whether it alters the risk of nontuberculous mycobacterial (NTM) isolation is unresolved. RESEARCH QUESTION: Is azithromycin exposure in the preceding year associated with incident respiratory NTM isolation in non-cystic fibrosis bronchiectasis and in COPD? STUDY DESIGN AND METHODS: Two nationwide register-based nested case-control analyses in Denmark. Case patients had a first positive respiratory culture for NTM; controls, alive and free of prior NTM isolation on the index date, were matched 1:20 on age, sex, and comorbidity index. The prespecified exposure was at least 3,000 mg of azithromycin with at least two prescriptions redeemed in the preceding 12 months, with a 3-month lag. Conditional logistic regression was adjusted for inhaled and oral corticosteroids. Exploratory analyses examined an active comparator at matched thresholds, recency, and outcome stringency. RESULTS: The analyses comprised 173 cases and 3,409 controls (bronchiectasis) and 365 and 7,300 (COPD). Under the prespecified definition, azithromycin was not associated with incident NTM isolation (bronchiectasis: OR, 1.31; 95% CI, 0.79-2.18; COPD: 1.29; 0.78-2.13). In COPD, the OR was 1.61 (1.14-2.28) for one or more prescriptions and 1.29 (0.78-2.13) for two or more. The COPD association was concentrated within 90 days of the index date (2.55; 1.73-3.76) and attenuated with microbiological stringency (definite isolates: 0.77; 0.27-2.20). Non-macrolide antibacterials were more strongly associated than azithromycin at every matched threshold in bronchiectasis (one or more prescriptions: 1.90 [1.36-2.65] vs 1.15 [0.75-1.75]), and at the two higher thresholds in COPD (two or more: 1.48 [1.17-1.86] vs 1.24 [0.75-2.05]). INTERPRETATION: Azithromycin was not associated with NTM isolation under the prespecified definition. Associations under broader definitions were not dose-dependent and clustered close to the index date, more consistent with indication-driven testing than a drug effect, although in COPD an association with any exposure persisted after accounting for other antibacterials.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Torsheim IL, Wedervang EB, Vognsen AK, et al. Azithromycin Exposure and Incident Nontuberculous Mycobacterial Isolation in Bronchiectasis and COPD: A Nationwide Nested Case-Control Study. Chest. 2026. PMID: 42951063. doi:10.1016/j.chest.2026.10.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。